Toni Choueiri, MD

Toni Choueiri, MD, discusses the significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Toni K. Choueiri, MD, discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC.

Toni K. Choueiri, MD, discusses data from the phase 3 LITESPARK-022 trial in ccRCC after nephrectomy.

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.

Toni Choueiri, MD, discusses the results of the phase 3 CONTACT-03 trial (NCT04338269) of atezolizumab and cabozantinib in patients with metastatic renal cell carcinoma.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Patients with metastatic renal cell carcinoma have a new frontline treatment alternative following FDA approval of the combination of nivolumab plus cabozantinib combination.

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Toni K. Choueiri, MD, discusses the significance of the COVID-19 and Cancer Consortium during the coronavirus disease 2019 pandemic.

Toni K. Choueiri, MD, discusses the impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma.

Toni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses the next generation of trials in renal cell carcinoma (RCC).

Toni Choueiri, MD, discusses the use of checkpoint inhibitors to treat patients with sarcomatoid carcinoma.